Colinz Laboratories Limited (BOM:531210)

India · Delayed Price · Currency is INR

72.56

+1.06 (1.48%)

At close: Sep 4, 2026

Market Cap	182.79M +75.9%
Revenue (ttm)	58.11M -8.4%
Net Income	27.97M +484.3%
EPS	11.11 +484.7%
Shares Out	2.52M
PE Ratio	6.53
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47
Open	72.93
Previous Close	71.50
Day's Range	72.56 - 73.65
52-Week Range	36.11 - 87.91
Beta	-0.09
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About Colinz Laboratories

Colinz Laboratories Limited manufactures and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, syrups, suppositories, etc.; and specialized products for gynaecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, pegylated liposome doxorubicin, etc.; an... [Read more]

Industry Pharmaceutical Preparations

Founded 1986

Employees 62

Stock Exchange Bombay Stock Exchange

Ticker Symbol 531210

Full Company Profile

Financial Performance

In fiscal year 2026, Colinz Laboratories's revenue was 61.36 million, a decrease of -6.00% compared to the previous year's 65.28 million. Earnings were 5.15 million, an increase of 3.60%.

Financial Statements